NCT06768658View on ClinicalTrials.gov

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Nausea and Vomitting

Interventions

DRUG

TAK-951

TAK-951 subcutaneous injection.

DRUG

TAK-951 Placebo

TAK-951 placebo-matching subcutaneous injection.

Trial Locations (1)

37909-1161

New Phase Research & Development, Knoxville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY